Broncus Holding Corporation Secures EU MDR CE Marking for BroncTru® Catheter: Significant Global Milestone
Key Highlights
- BroncTru® Disposable Transbronchial Puncture Dilation Catheter, developed by Broncus Holding Corporation, has officially received the European Union Medical Device Regulation (EU MDR) CE marking.
- This achievement represents a major advancement in international registration and enhances the company’s global product presence.
- BroncTru® utilizes multiple patented technologies, enabling precise access to peripheral pulmonary nodules that are otherwise unreachable by conventional bronchoscopes.
- The catheter creates a direct working channel through puncture, dilation, and tunnel creation, supporting Bronchoscopic Transparenchymal Nodule Access (BTPNA).
- BroncTru® can be combined with other diagnostic and therapeutic products to accelerate diagnosis and treatment for various lung lesions.
- Wide Application Scenarios: Includes biopsy and sampling procedures such as:
- Endobronchial ultrasound-guided transbronchial tunnel cryobiopsy (EBUS-TTCB)
- Endobronchial ultrasound-guided sheath transbronchial lung biopsy (EBUS-GS-TBLB)
- Transbronchial needle aspiration (TBNA)
- Bronchoscopic lung cavity puncture biopsy and lavage
- Transbronchoscopic targeted drug delivery
- Transbronchoscopic ablation procedures
- Transbronchoscopic-assisted localization
- BroncTru® comprehensively meets diverse clinical diagnostic and therapeutic needs.
Important Information for Shareholders
- The EU MDR CE marking is a mandatory qualification for medical devices entering the European market and confirms BroncTru®’s compliance with the latest regulatory standards.
- This regulatory milestone lays a solid foundation for the company’s further expansion into Europe and other CE-recognizing markets, potentially unlocking significant new revenue streams.
- The global commercialization capabilities and competitiveness of Broncus Holding Corporation are notably enhanced, strengthening its international portfolio.
- BroncTru® is now approved and registered with:
- National Medical Products Administration (NMPA) of China
- U.S. Food and Drug Administration (FDA)
- EU MDR CE
- Marketing approvals in Taiwan, China, Indonesia, Thailand, and Malaysia
- Investors should note that regulatory approvals in multiple key markets can accelerate sales, market penetration, and commercial growth for Broncus, which may positively influence share value.
- The announcement advises shareholders and potential investors to exercise caution when trading shares, highlighting the importance and potential impact of this news.
Board and Management Update
- Chairman: Xu Hong
- Board composition includes:
- Executive Director: Mr. Hong Xu
- Non-executive Directors: Mr. Ao Zhang, Ms. Yanhong Kuang
- Independent Non-executive Directors: Dr. Pok Man Kam, Ms. Yee Sin Wong, Dr. David Scott Lim
Analysis and Potential Share Price Impact
The receipt of the EU MDR CE marking is a material event for Broncus Holding Corporation. It significantly strengthens the company’s regulatory standing in Europe and other markets, potentially driving new sales, partnerships, and adoption of BroncTru®. The expansion of product registration across major global territories is likely to bolster revenue growth and market share, making this announcement potentially price-sensitive and relevant for current and prospective shareholders.
Disclaimer
This article is for informational purposes only and does not constitute investment advice. Shareholders and potential investors should exercise caution and conduct their own research before making investment decisions.
堃博醫療控股公司 BroncTru®導管獲得歐盟MDR CE認證：全球發展重大突破
重點摘要
- 堃博醫療控股公司自主研發的 BroncTru® 一次性經支氣管穿刺擴張導管，正式取得歐盟醫療器械法規（EU MDR）CE標誌。
- 這一成就代表公司在國際註冊及全球產品佈局上取得重大突破。
- BroncTru® 採用多項專利技術，能精確到達傳統支氣管鏡難以觸及的肺部周邊結節。
- 導管通過穿刺、擴張、隧道建立，開闢直接工作通道，支援支氣管鏡經肺實質結節進入（BTPNA）。
- BroncTru® 可與其他診斷及治療產品結合，加快肺部病變的診斷與治療。
- 廣泛應用場景：包括各種活檢及採樣程序，如：
- 支氣管鏡超聲引導經支氣管隧道冷凍活檢（EBUS-TTCB）
- 支氣管鏡超聲引導鞘經支氣管肺活檢（EBUS-GS-TBLB）
- 經支氣管針吸（TBNA）
- 支氣管鏡肺腔穿刺活檢及灌洗
- 經支氣管擴張導管靶向藥物遞送
- 經支氣管消融手術
- 經支氣管協助定位
- BroncTru® 能全面滿足不同臨床診斷和治療需求。
股東須知的重要信息
- EU MDR CE 認證是醫療器械進入歐洲市場的強制資格，證明 BroncTru® 符合最新法規要求。
- 該認證為公司進一步拓展歐洲及其他認可CE標誌市場打下堅實基礎，或將帶來顯著新增收入來源。
- 堃博醫療控股公司全球商業化能力及競爭力顯著提升，國際產品組合更加豐富。
- BroncTru® 現已獲得多地註冊與上市批准：
- 中國國家藥品監督管理局（NMPA）
- 美國食品藥品監督管理局（FDA）
- 歐盟MDR CE
- 台灣、中國、印尼、泰國、馬來西亞上市批准
- 多國市場註冊有望加速銷售、市場滲透及商業增長，對股價或有正面影響。
- 公告提醒股東及潛在投資者交易公司股份時需謹慎，突顯本次消息的重要性及潛在影響。
董事會及管理層最新動態
- 主席：徐洪
- 董事會成員包括：
- 執行董事：徐洪先生
- 非執行董事：張傲先生、鄺燕紅女士
- 獨立非執行董事：甘博文博士、黃綺先女士、林大衛博士
分析及股價潛在影響
EU MDR CE 認證屬於重大利好事件，大幅提升公司在歐洲及其他市場的監管地位，有望帶動新銷售、合作及 BroncTru® 應用普及。產品註冊覆蓋全球主要地區，預計將促進收入增長及市場份額擴大，該消息具價格敏感性，值得現有及潛在股東關注。
免責聲明
本文僅供參考，不構成任何投資建議。股東及潛在投資者請謹慎行事，並自行作出研究及判斷。
